Prevencio and Quadrant Health Announce Partnership to Integrate HART CVE and HART CADhs AI-Blood Tests into Primary Care
Partnership expands access to AI cardiometabolic risk insights to support earlier detection, clearer triage, and more personalized care pathways
KIRKLAND, WA, UNITED STATES, January 8, 2026 /EINPresswire.com/ — Prevencio, Inc., a leader in advanced, AI-driven multiprotein-based cardiovascular and cardiometabolic risk assessment, and Quadrant Health today announced a partnership agreement to integrate Prevencio’s HART® CVE and HART® CADhs blood tests into Quadrant Health’s primary care model.
The collaboration is designed to help primary care teams identify cardiometabolic and cardiovascular risk earlier and act with greater confidence by pairing Prevencio’s biomarker-driven insights with Quadrant Health’s care delivery pathways and patient engagement approach.
